Femasys Appoints Fred Aslan and Charles Larsen to its Board of Directors
Atlanta, GA, March 22, 2016 Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced that Fred Aslan, Founder and Chief Executive Officer of Advance Medical, Inc. and Vice President of Venrock and Charles E. Larsen, Managing Director of Accuitive Medical Ventures, have been appointed to the Femasys Board of Directors. Both new directors bring significant leadership, operations and commercial experience to Femasys as the Company prepares to commence its pivotal trial of FemBloc™ which is designed to provide women with the first non-surgical permanent contraception option delivered exclusively in the office.
Femasys Announces Todd Creech as Chief Financial Officer
ATLANTA, GA, December 14, 2015 - Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys' principal financial and accounting officer, will report to Kathy Lee-Sepsick, President and CEO, and will be responsible for all financing, accounting, corporate development and investor activities.
Femasys Secures Term Loan Facility from Silicon Valley Bank
ATLANTA, GA, July 9, 2015 - Femasys Inc., a developer of innovative medical devices for the women's healthcare market, announced today that it has secured a term loan facility from Silicon Valley Bank. Under the loan facility, the company received initial funding and a conditional option to receive additional funding. The Company will use the funds for working capital as it supports the advancement of its groundbreaking non-surgical female sterilization device.
Femasys Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
ATLANTA, GA, January 4, 2018 -Femasys Inc., a developer of innovative medical solutions for the women's healthcare market, today announced that its Chief Executive Officer and President, Kathy Lee-Sepsick, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 2:30 p.m. PST at the Westin St. Francis Hotel, in San Francisco, CA.
Femasys Announces $40 Million in Series C Financing to Complete Development of FemBloc™
Funding to support pivotal testing of non-surgical permanent contraception solution FemBloc™ -
- IDE approval granted by FDA for U.S. clinical trial of FemBloc; study to start early 2017 -
ATLANTA, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company. The funding will be used primarily to support the pivotal testing of FemBloc™, the Company's revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician's office.